Together with the Shenzhen Hospital of Peking University to benefit patients with blood diseases

Jingbao News (Reporter Yan Shanshan Xie Qun) On August 8th, Ms. Li Ke, Executive Vice President of BYD Group donated 500,000 A -share shares (market value of about 160 million yuan) to the Shenzhen Hospital of Peking University for it for The "BYD Charity Foundation 'Li Anzhen' Hematoptis" Center of the BYD Charity Foundation "was established. On the morning of the same day, the donation ceremony was held at the Shenzhen Hospital of Peking University.

It is reported that this donation will be used to support the blood in the Shenzhen Hospital of Peking University. By improving the precision diagnosis, targeted therapy, hematopoietic stem cell transplantation, new immunotherapy treatment, etc. Store -edge technology, carry out the prevention, treatment, basic research, clinical research, and talent introduction of related diseases to benefit patients with blood tumors.

As a director of the BYD Charity Foundation, Ms. Li Ke enthusiastically charitable public welfare, as early as the early days of the BYD Charity Foundation, began her charity. According to Li Ke, the donation of this project originated from Ms. Li Anzhen's blood in the blood in Shenzhen Hospital at Peking University. In the meantime, Ms. Li Ke deeply felt the limitations of blood disease treatment technology. It is hoped that through charity projects, she can help Peking University Shenzhen Hospital's blood in the Department of Hospital of Hospital of Hospitals to continuously explore new technologies and innovative therapies, bringing the dawn of survival to patients with advanced tumors.

It is understood that the Department of Hematology of Shenzhen Hospital of Peking University is in the advanced position in South China in the diagnosis of lymphoma, the clinical research of hematological and immune cell therapy, and has successfully launched the world's leading clinical research on difficult diseases such as CAR-T cell cure lymphoma. At the donation ceremony, Chen Yun, the dean of Shenzhen Hospital of Peking University, said that the hospital will take this as an opportunity to fully integrate the hospital's national and provincial cell treatment transformation and innovation platform, actively explore new technologies and innovative research, and strengthen talent introduction and training. Improving the clinical service capabilities, scientific research and innovation capabilities, and talent training capabilities of hematological treatment, continuously improve the medical environment and humanistic care level, and provide cutting -edge treatment and high -quality services for patients with the Guangdong -Hong Kong -Macao Greater Bay Area and even blood diseases at home and abroad.

- END -